Potassium Channel News and Research RSS Feed - Potassium Channel News and Research

Tannic acid may help ease impact of bacterial lung infections in CF patients

Tannic acid may help ease impact of bacterial lung infections in CF patients

By screening over 2,000 approved drugs and natural products, scientists have shown that tannic acid may help ease the impact of bacterial lung infections in cystic fibrosis patients. [More]
Empirical sulphonylurea therapy an option for neonatal diabetes

Empirical sulphonylurea therapy an option for neonatal diabetes

A report of empirical sulphonylurea therapy in neonatal diabetes prior to genetic diagnosis highlights contrasting approaches to the problem. [More]
Mice who have partial deficiency of gene SENP2 are more likely to develop seizures, sudden death

Mice who have partial deficiency of gene SENP2 are more likely to develop seizures, sudden death

A gene crucial for brain and heart development may also be associated with sudden unexplained death in epilepsy (SUDEP), the most common cause of early mortality in epilepsy patients. [More]
Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus. [More]
Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. [More]
Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. [More]

Researchers discover that anti-seizure drug reduces alcohol consumption

Boston-Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug and Alcohol Abuse, may lead to more effective treatments for alcoholism. [More]
Servier Joins Xention To Develop AF Drug In Up To $163.2M Deal

Servier Joins Xention To Develop AF Drug In Up To $163.2M Deal

... [More]
Research discovery could shed light on unsolved cases of arrhythmia

Research discovery could shed light on unsolved cases of arrhythmia

The heart's regular rhythm is crucial to the delivery of oxygenated blood and nutrients to all the organs of the body. It is regulated by a bundle of cells called "the pacemaker," which use electrical signals to set the pace of the heart. Dysfunction in this mechanism can lead to an irregular heartbeat, known as arrhythmia, and often necessitates the implantation of an artificial pacemaker. [More]
Study reveals that an epilepsy drug shows promise in preventing noise-induced tinnitus

Study reveals that an epilepsy drug shows promise in preventing noise-induced tinnitus

An epilepsy drug shows promise in an animal model at preventing tinnitus from developing after exposure to loud noise, according to a new study by researchers at the University of Pittsburgh School of Medicine. [More]
Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance. [More]
Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits. [More]
Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Study shows how fish oils help lower blood pressure via vasodilation at ion channels

Omega-3 fatty acids found in oily fish may have diverse health-promoting effects, potentially protecting the immune, nervous, and cardiovascular systems. [More]
Scientists decode the antihypertensive impact of omega-3 fatty acids

Scientists decode the antihypertensive impact of omega-3 fatty acids

Scientists of Friedrich Schiller University Jena and Jena University Hospital decode the antihypertensive impact of omega-3 fatty acids. In two newly published articles for the well-known science magazine 'Proceedings of the National Academy of Sciences, USA' they describe how they analyzed the impact of omega-3 fatty acids on a systemic level and they also described the underlying molecular mechanisms for the first time. [More]
Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo Pharmaceuticals, Inc. today announced that RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012. [More]
Activation of SK channels can lead to heart disease

Activation of SK channels can lead to heart disease

Qing-Hui Chen's research focuses on hypertension, heart failure and the neuromechanisms that underlie these problems. Specifically, his research examines how a particular ion channel (that regulates resting and action in membranes)—the potassium channel (SK)—is linked to heart disease. [More]
Scientists identify cause of certain forms of epilepsy in cats

Scientists identify cause of certain forms of epilepsy in cats

There is something sinister about epilepsy: the disease affects the very core of our being, our brain. Epileptic attacks can lead to seizures throughout the body or in parts of it. Clouding of consciousness or memory lapses are also possible. The causes are still only partially understood but in some cases brain tumours, infections, inflammations of the brain or metabolic diseases have been implicated. [More]
Bioelectric signals can identify cells that are likely to develop into tumors

Bioelectric signals can identify cells that are likely to develop into tumors

Biologists at Tufts University School of Arts and Sciences have discovered a bioelectric signal that can identify cells that are likely to develop into tumors. The researchers also found that they could lower the incidence of cancerous cells by manipulating the electrical charge across cells' membranes. [More]
Rethinking therapy decisions in autoimmune encephalopathy

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy. [More]
Study finds mechanism that mediates inhibition of critical breathing muscles during REM sleep

Study finds mechanism that mediates inhibition of critical breathing muscles during REM sleep

A novel brain mechanism mediating the inhibition of the critical breathing muscles during rapid eye movement (REM) sleep has been identified for the first time in a new study, offering the possibility of a new treatment target for sleep-related breathing problems. [More]